Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 28Burkitt Lymphoma 20Leukemia, Myeloid, Acute 11Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 7Myeloproliferative Disorders 5Myelodysplastic Syndromes 5Lymphoma, Non-Hodgkin 5Lymphoma, Mantle-Cell 5Lymphoma, Large B-Cell, Diffuse 5Leukemia, Myelomonocytic, Chronic 5Leukemia, Myeloid, Accelerated Phase 5Leukemia, Lymphocytic, Chronic, B-Cell 5Leukemia, Biphenotypic, Acute 5Hodgkin Disease 5Congenital Abnormalities 5Lymphoma, Large-Cell, Anaplastic 4Leukemia, Myelogenous, Chronic, BCR-ABL Positive 4Blast Crisis 4Anemia, Refractory, with Excess of Blasts 4Lymphoma, Large-Cell, Immunoblastic 3Lymphoma, Follicular 3Lymphoma, B-Cell, Marginal Zone 3Lymphoma 3Hematologic Neoplasms 3Chromosome 5q Deletion Syndrome 3Breast Neoplasms 3Waldenstrom Macroglobulinemia 2Sezary Syndrome 2Recurrence 2Primary Myelofibrosis 2

Interventions

Carboplatin 23Cisplatin 19pembrolizumab 14Paclitaxel 12Gemcitabine 12Pemetrexed 11130-nm albumin-bound paclitaxel 9Everolimus 8Cetuximab 8Fluorouracil 7Axitinib 6osimertinib 5durvalumab 5Sunitinib 5Radiotherapy 5Erlotinib Hydrochloride 5Docetaxel 5Cyclophosphamide 5Albumin-Bound Paclitaxel 5Sorafenib 4Radiation 4Nivolumab 4Ipilimumab 4vosaroxin 3Radiotherapy, Intensity-Modulated 3Octreotide 3Irinotecan 3Bevacizumab 31-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 3pralsetinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Carcinoma × merphos × Clear all
NCT02412670 2023-07-10

Chemotherapy Before Surgery in Treating Patients With High Grade Upper Urinary Tract Cancer

Eastern Cooperative Oncology Group

Phase 2 Completed
36 enrolled 14 charts
Tumor-Agnostic

Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡